- Home
- CSQ vs KNSA Comparison
CSQ vs KNSA Comparison
Compare CSQ & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | KNSA |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CSQ | KNSA |
|---|---|---|
| Price | $17.88 | $46.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $55.29 |
| AVG Volume (30 Days) | 252.0K | ★ 633.5K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | N/A | $17.42 |
| P/E Ratio | ★ N/A | $61.07 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $13.11 | $18.26 |
| 52 Week High | $19.83 | $49.12 |
Technical Indicators
Market Signals| Indicator | CSQ | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 55.66 |
| Support Level | $17.29 | $39.96 |
| Resistance Level | $19.48 | $49.12 |
| Average True Range (ATR) | 0.30 | 1.91 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 9.70 | 78.00 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.